Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevasemten Phase 1 Study in Healthy Volunteers and Becker Muscular Dystrophy
NCT04585464Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sevasemten in Becker muscular dystrophy (BMD) (3 arms). Primary endpoints: Incidence, frequency, severity and dose-relationship of adverse events up to 42 days, Incidence of abnormal laboratory test results up to 42 days and 3 more. Started Oct 2020; status: completed.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on NCT04585464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585464.